GlassScriptPhysician profile
Maryam Phillips
NPI 1447578372
$4,763.89
in general payments reported to CMS, 2019-2025
35 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $526 · 2021: $690 · 2022: $865 · 2023: $629 · 2024: $910 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $815.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $703.10 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $535.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $513.39 | 2021-2025 | |
| Lilly USA, LLC | $365.76 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $228.40 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.04 | 2019-2024 | Jardiance, Synjardy |
| Pfizer INC. | $185.48 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.28 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $111.42 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $104.26 | 2019-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $90.08 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Phadia US INC. | $75.64 | 2019-2022 | |
| Amarin Pharma, INC. | $71.33 | 2020-2021 | |
| Hologic Sales and Service, LLC | $57.69 | 2022-2025 | Aptima, Thinprep 2000 Processor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kvk-Tech, INC. | $55.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.19 | 2022 | |
| Allergan, INC. | $43.63 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.72 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.14 | 2024 | Caplyta |
| Shield Therapeutics INC | $32.84 | 2022-2024 | |
| Medtronic, INC. | $26.46 | 2022-2024 | Abre |
| Acadia Pharmaceuticals INC | $22.84 | 2024 | Nuplazid |
| C2n Diagnostics, LLC | $21.58 | 2025 | Precivityad2 |
| Corcept Therapeutics | $21.05 | 2025 | Korlym |
| Dexcom, INC. | $19.92 | 2025 | Dexcom G6 Transmitter |
| Mckesson Medical-Surgical, INC. | $19.35 | 2023 | |
| Galderma Laboratories, L.P. | $19.14 | 2025 | Dysport |
| Esperion Therapeutics, INC. | $18.17 | 2025 | Nexletol |
| Biogen, INC. | $18.01 | 2024 | Leqembi |
| Organon LLC | $15.89 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.65 | 2024 | |
| Astellas Pharma US INC | $14.90 | 2023 | Veozah |
| Echosens North America, INC. | $14.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.